GLYXAMBI 25MG/5MG TABLETS (Empagliflozin + Linagliptin) Diabetes
GLYXAMBI 25MG/5MG TABLETS contain Empagliflozin 25mg and Linagliptin 5mg, an antidiabetic combination prescribed to improve blood glucose control in adults with type 2 diabetes mellitus.
GLYXAMBI 25MG/5MG TABLETS
GLYXAMBI 25MG/5MG TABLETS (EMPAGLIFLOZIN 25MG + LINAGLIPTIN 5MG): Comprehensive Guide and Benefits
Introduction to GLYXAMBI 25MG/5MG TABLETS (EMPAGLIFLOZIN 25MG + LINAGLIPTIN 5MG)
GLYXAMBI 25MG/5MG TABLETS (EMPAGLIFLOZIN 25MG + LINAGLIPTIN 5MG): A Diabetes Medication (SGLT2 Inhibitor + DPP-4 Inhibitor Combination)
GLYXAMBI 25MG/5MG TABLETS contain a fixed-dose combination of Empagliflozin 25mg and Linagliptin 5mg, belonging to the oral antidiabetic medication class. This combination is prescribed to improve blood sugar control in adults with type 2 diabetes mellitus when diet, exercise, and other diabetes medicines do not provide adequate glycemic control.
Empagliflozin belongs to the SGLT2 inhibitor class and helps remove excess glucose through urine, while Linagliptin is a DPP-4 inhibitor that improves insulin regulation by enhancing incretin activity. GLYXAMBI is a prescription-only medicine and should be used under medical supervision with regular monitoring of blood glucose levels and kidney function when required.
Key Benefits of GLYXAMBI 25MG/5MG TABLETS (EMPAGLIFLOZIN + LINAGLIPTIN)
Helps improve blood glucose control in adults with type 2 diabetes.
Provides dual-action glucose management through two complementary mechanisms.
Helps reduce excess glucose levels by increasing urinary glucose removal.
Supports improved insulin response and glucose regulation.
Offers a convenient once-daily combination therapy option when prescribed.
How GLYXAMBI 25MG/5MG TABLETS (EMPAGLIFLOZIN + LINAGLIPTIN) Works
GLYXAMBI combines two medicines that act through different pathways to control blood glucose. Empagliflozin inhibits the sodium-glucose cotransporter-2 (SGLT2) in the kidneys, reducing glucose reabsorption and increasing glucose elimination through urine. Linagliptin inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme, which increases incretin hormone activity, helping stimulate glucose-dependent insulin release and reduce excessive glucagon secretion. Together, these actions help improve glycemic control in patients with type 2 diabetes.
Usage Instructions for GLYXAMBI 25MG/5MG TABLETS (EMPAGLIFLOZIN + LINAGLIPTIN)
Take GLYXAMBI 25MG/5MG TABLETS exactly as prescribed by your doctor.
Swallow the tablet whole with water; do not crush, chew, or break it.
Take the medicine once daily at the recommended time, with or without food.
Monitor blood sugar levels and kidney function as advised by your healthcare provider.
Do not stop or change the dose without medical guidance.
Medicinal Advantages of GLYXAMBI 25MG/5MG TABLETS (EMPAGLIFLOZIN + LINAGLIPTIN)
Helps achieve better blood glucose control in type 2 diabetes management.
Provides complementary effects through SGLT2 and DPP-4 inhibition.
May help reduce glucose levels without directly increasing insulin doses.
Supports individualized diabetes treatment plans.
Provides an established oral combination therapy for eligible patients.
NOTE: GLYXAMBI 25MG/5MG TABLETS are prescription-only medicines. They are not used for type 1 diabetes and require medical supervision. Patients should inform their doctor about kidney problems, dehydration risk, or recurrent urinary/genital infections before use.
Off-Label Uses of GLYXAMBI 25MG/5MG TABLETS (EMPAGLIFLOZIN + LINAGLIPTIN)
Healthcare professionals may occasionally prescribe components of this combination for conditions outside approved indications based on clinical judgment and patient-specific factors.
Selected metabolic conditions requiring glucose regulation.
Specialist-guided diabetes-related treatment strategies.
Individualized management approaches in complex diabetic patients.
Disclaimer: Off-label uses should only occur under physician supervision and may not be approved in all countries.
Expert Advice for Optimal Use
Take GLYXAMBI regularly as prescribed.
Maintain a balanced diet and regular physical activity as advised.
Monitor blood glucose levels consistently.
Drink adequate fluids unless fluid restriction is recommended.
Inform your doctor before surgery or prolonged fasting.
Report symptoms such as dehydration, urinary infections, or unusual weakness promptly.
Precautions
Cardiovascular Health
Patients with heart disease or cardiovascular risk factors should inform their healthcare provider before starting treatment. Regular diabetes and cardiovascular monitoring may be required.
Liver & Kidney Function
Kidney function should be evaluated before and during treatment when clinically indicated. GLYXAMBI may not be suitable for some patients with severe kidney impairment. Liver conditions should also be discussed with a doctor before use.
Pregnancy & Breastfeeding
GLYXAMBI is generally not recommended during pregnancy unless specifically advised by a healthcare professional. Breastfeeding women should consult their doctor before use.
Drug Interactions
GLYXAMBI may interact with insulin, sulfonylureas, diuretics, and other glucose-lowering medicines. Inform your healthcare provider about all medicines and supplements you take.
Existing Medical Conditions
Tell your doctor if you have kidney disease, urinary tract infections, pancreatic disorders, dehydration, diabetic ketoacidosis history, or other significant medical conditions.
Storage Instructions
Store below 30°C.
Keep tablets in the original blister packaging.
Protect from moisture and direct sunlight.
Keep out of reach of children.
Do not use after the expiry date.
Frequently Asked Questions (FAQs)
Q: What is GLYXAMBI 25MG/5MG TABLETS used for?
A: GLYXAMBI 25MG/5MG TABLETS are used to improve blood sugar control in adults with type 2 diabetes mellitus along with diet and exercise.
Q: What are the active ingredients in GLYXAMBI?
A: GLYXAMBI contains Empagliflozin 25mg and Linagliptin 5mg.
Q: Is GLYXAMBI an insulin medicine?
A: No. GLYXAMBI is an oral antidiabetic combination containing an SGLT2 inhibitor and a DPP-4 inhibitor.
Q: How does GLYXAMBI help control blood sugar?
A: Empagliflozin removes excess glucose through urine, while Linagliptin improves insulin regulation through DPP-4 inhibition.
Q: Can GLYXAMBI cause low blood sugar?
A: Low blood sugar may occur, especially when used with insulin or certain other diabetes medicines. Consult your doctor if symptoms occur.
Q: Can GLYXAMBI be stopped suddenly?
A: Do not stop GLYXAMBI without medical advice, as blood glucose levels may increase.
Q: Is GLYXAMBI available without prescription?
A: No. GLYXAMBI is a prescription medicine and should be used only under healthcare professional supervision.
Product Tags
GLYXAMBI 25MG/5MG TABLETS, Empagliflozin 25mg Linagliptin 5mg, Empagliflozin Tablet, Linagliptin Tablet, Diabetes Medication, Type 2 Diabetes Treatment, Antidiabetic Medicine, SGLT2 Inhibitor, DPP-4 Inhibitor, Blood Sugar Control Tablet, Oral Diabetes Medicine, Glycemic Control Therapy, GLYXAMBI Tablet, Prescription Diabetes Medicine, Diabetes Management Tablet, Glucose Lowering Medicine, Empagliflozin Linagliptin Combination, Type 2 Diabetes Tablet, Diabetic Care Medicine, Cardiometabolic Health Support.
